The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm‐Score), which was based on the combination of the albumin level, lactate dehydrogenase, neutrophil‐to‐lymphocyte ratio, aspartate aminotransferase‐to‐alanine aminotransferase ratio, and total bilirubin level, serves as a novel prognostic score for HCC patients treated with atezolizumab and bevacizumab. The gene discussed is ALB; the disease is hepatocellular carcinoma.